|
Anti-Xa activity before (0 h) and 3, 4, 6, 8, 12 and 24 h after subcutaneous administration of 2,500 IU dalteparin |
||||||||
| Anti-Xa activity (IU/ml) |
||||||||
|
|
||||||||
| 0 h |
3 h |
4 h |
6 h |
8 h |
12 h |
24 h |
AUC(0–24 h) |
|
|
|
||||||||
| Index: with oedema |
||||||||
| 1 |
0.01 |
0.18 |
0.14 |
0.03 |
0.06 |
0.02 |
0.01 |
1.05 |
| 2 |
0.00 |
0.20 |
0.17 |
0.08 |
0.03 |
0.00 |
0.00 |
0.91 |
| 3 |
0.02 |
0.15 |
0.11 |
0.10 |
0.04 |
0.03 |
0.06 |
1.42 |
| 4 |
0.06 |
0.16 |
0.14 |
0.12 |
0.09 |
0.02 |
0.04 |
1.53 |
| 5 |
0.03 |
0.04 |
0.02 |
0.03 |
0.03 |
0.02 |
0.02 |
0.59 |
| 6 |
0.00 |
0.14 |
0.12 |
0.12 |
0.10 |
0.12 |
0.17 |
2.98 |
| 7 |
0.10 |
0.20 |
-a |
0.11 |
0.10 |
0.07 |
0.03 |
2.07 |
| Mean (SD) |
0.03 (0.02) |
0.15 (0.05) |
0.12 (0.05) |
0.08 (0.04) |
0.06 (0.03) |
0.04 (0.04) |
0.05 (0.06) |
1.50 (0.81) |
| Reference: without oedema |
||||||||
| 1 |
0.00 |
0.09 |
0.08 |
0.05 |
0.01 |
0.00 |
0.00 |
0.43 |
| 2 |
0.01 |
0.14 |
0.13 |
0.09 |
0.07 |
0.03 |
0.02 |
1.24 |
| 3 |
0.00 |
0.25 |
0.16 |
0.08 |
0.03 |
0.00 |
0.00 |
0.99 |
| 4 |
0.01 |
0.10 |
0.09 |
0.07 |
0.05 |
0.03 |
0.00 |
0.88 |
| 5 |
0.04 |
0.08 |
0.09 |
0.09 |
0.05 |
0.03 |
0.02 |
1.05 |
| 6 |
0.02 |
0.13 |
0.09 |
0.05 |
0.04 |
0.02 |
0.02 |
0.93 |
| 7 |
0.04 |
0.18 |
0.16 |
0.15 |
0.12 |
-a |
0.06 |
2.52 |
| Mean (SD) |
0.02 (0.02) |
0.14 (0.06) |
0.11 (0.04) |
0.08 (0.03) |
0.05 (0.03) |
0.02 (0.01) |
0.02 (0.02) |
1.15 (0.65) |
|
aMissing value. AUC, area under the concentration curve; SD, standard deviation. | ||||||||
Rommers et al. Critical Care 2006 10:R93 doi:10.1186/cc4952 |
||||||||